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Abstract 
Objective: The WNT signaling pathway effector gene TCF7L2 has been associated with an 
increased risk of type 2 diabetes. However, it remains unclear how this gene affects diabetic 
pathogenesis. The goal of this study was to investigate the effects of Tcf7l2 haploinsufficiency 
on metabolic phenotypes in mice.  
Experimental Design: Tcf7l2 knockout (Tcf7l
-/-) mice were generated. Because of the early 
mortality  of  Tcf7l2
-/-  mice,  we  characterized  the  metabolic  phenotypes of  heterozygous 
Tcf7l2
+/- mice in comparison to the wild-type controls. The mice were fed a normal chow diet 
or a high fat diet (HFD) for 9 weeks.  
Results: The Tcf7l2
+/- mice showed significant differences from the wild-type mice with re-
gards to body weight, fasting glucose and insulin levels. Tcf7l2
+/- mice displayed improved 
glucose tolerance. In the liver of Tcf7l2
+/- mice fed on the HFD, reduced lipogenesis and 
hepatic triglyceride levels were observed when compared with those of wild-type mice. 
Furthermore, the Tcf7l2
+/- mice fed on the HFD exhibited decreased peripheral fat deposition. 
Immunohistochemistry in mouse pancreatic islets showed that endogenous expression of 
Tcf7l2 was upregulated in the wild-type mice, but not in the Tcf7l2
+/- mice, after feeding with 
the HFD. However, the haploinsufficiency of Tcf7l2 in mouse pancreatic islets resulted in little 
changes in glucose-stimulated insulin secretion.  
Conclusion: These results suggest that decreased expression of Tcf7l2 confers reduction of 
diabetic susceptibility in mice via regulation on the metabolism of glucose and lipid. 
Key words: Tcf7l2, diabetes, high fat diet, glucose tolerance, gluconeogenesis, hepatic steatosis. 
Introduction 
Transcription factor 7-like 2 (TCF7L2, formerly 
called  TCF4)  is  a  member  of  the  T-cell-specific 
high-mobility group (HMG) box-containing family of 
transcription factors that plays an important role in 
downstream  signals  of  the  canonical  morphogenic 
wingless-type MMTV integration site family (WNT) 
pathway [1]. The WNT signaling pathway has been 
well known to be associated with the developmental 
pathways  such  as  embryogenesis  including  adipo-
genesis  and  pancreatic  islet  development,  and  tu-
morigenesis [2-5]. Activation of this pathway leads to 
accumulation of β-catenin in the nucleus, which in-
teracts with the T-cell factor/lymphoid enhancer fac-
tor (TCF/LEF) family of transcription factors to reg-
ulate the transcription of WNT target genes, many of 
which are associated with the cell proliferation and 
cell fate decision [1,6].  
Besides the developmental role, several lines of 
evidence suggest the role of WNT signaling pathway 
in the etiology of metabolic disorders [7-10]. Particu-
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larly,  single  nucleotide  polymorphisms  (SNPs)  in 
human TCF7L2 gene are known to be strongly asso-
ciated  with  an  increased  risk  of  type  2  diabetes 
through  the  extensive  genome-wide  association 
studies in multiple ethnic populations [11-13]. TCF7L2 
variants have been associated with an impaired β-cell 
function including the impaired insulin secretion and 
processing,  an  increased  insulin  resistance,  and  hy-
perglycemia  [14-16].  Yet,  the  mechanisms  by  which 
TCF7L2 gene function and its genetic polymorphisms 
affect the susceptibility to type 2 diabetes remain elu-
sive. There are conflicting reports regarding the role 
of TCF7L2 expression in increase in diabetes risk ver-
sus resistance to diabetes. Several reports have sug-
gested that TCF7L2 expression is upregulated in the 
pancreatic islet from diabetic subjects and negatively 
correlated  with  insulin  secretion  [16-18].  In  other 
context, however, TCF7L2 has been considered to be 
necessary in regulation of β-cell survival and function 
in human pancreatic islets, and a decreased TCF7L2 
protein expression has been suggested to be respon-
sible for the reduced islet insulin secretion in response 
to glucose through impaired GLP-1 signaling [19, 20]. 
To understand the mechanism underlying how 
TCF7L2 function change contributes to susceptibility 
to metabolic derangements and diabetes, we analyzed 
the  metabolic  phenotypes  of  the  mice  with  Tcf7l2 
haploinsufficiency  in  comparison  to  the  wild-type 
mice. In particular, we sought to demonstrate a role of 
TCF7L2 in the regulation of glucose and lipid metab-
olism. 
Materials and methods 
Generation of Tcf7l2 Knockout Mice 
Tcf7l2 knockout mice (Tcf7l2-/-) were generated 
via  the  International  Knockout  Mouse  Consortium 
(http://www.knockoutmouse.org).  The  procedure 
involved the insertion of a LoxP site together with a 
Flippase Recognition Target (FRT) flanked neomycin 
selection cassette within the intron 4 of mouse Tcf7l2 
gene and a single distal LoxP in the intron 5 down-
stream of exon 5 (Figure 1A). The animals used in the 
present  study  were  derived  from  heterozygous 
Tcf7l2+/- and wild-type C57BL/6 breeding pairs. The 
genotype of all progeny was confirmed by PCR anal-
ysis of DNA extracted from tail biopsies. All proce-
dures  were  performed  in  accordance  with  NIH 
guidelines  for  animal  experimentation,  and  all  ex-
perimental  protocols  were  approved  by  the  Institu-
tional Animal Care and Use Committee (IACUC) of 
the School of Pharmacy, University of Maryland Bal-
timore.  Animals  were  housed  4-5  mice/cage  and 
maintained under standard laboratory conditions (21 
 2 C, humidity 60  10% and 12 h / 12 h dark / light 
cycle) with food and water provided  ad libitum. All 
animals  used  in  the  present  study  were  male  mice 
with  the  same  genetic  background  of  C57BL/6. 
Wild-type and Tcf7l2+/- groups were matched for ages 
in all experiments. Mice were fed a normal chow diet 
for 11 weeks or a high-fat diet (HFD) from 13 weeks of 
ages for 9 weeks, which were purchased from Harlan 
Laboratories. The HFD consisted of 45 kcal% fat, 14.8 
kcal% protein and 41 kcal% carbohydrate (4.7 kcal/g), 
whereas  normal  chow  diet  contained  18  kcal%  fat, 
24%  kcal  protein,  and  58  kcal%  carbohydrate  (3.1 
kcal/g). For each experiment, animals were brought 
into  the experimental room 30 min prior to  the ex-
periment in order for them to acclimate to the envi-
ronment. Body weight was determined once a week at 
the same time each week.  
Glucose Tolerance Test and Insulin Meaure-
ment 
Glucose tolerance tests were carried out in the 
mice at 11 weeks of age under a normal chow diet or 
22 weeks of age after 9 weeks on the HFD. Mice were 
fasted overnight, and then intraperitoneally injected 
with 2 g/kg  glucose in saline. Blood  glucose levels 
were  analyzed  using  a  glucometer  (TRUEresult, 
HOMEdiagnostics). To measure insulin levels, blood 
was taken by tail bleeding, collected in microcentri-
fuge tubes  and placed on ice. Following immediate 
centrifugation at 4°C, serum was separated and stored 
at -80 °C until analysis. Insulin was determined using 
a rat/mouse insulin ELISA kit from Mercodia.  
Primary Mouse Hepatocyte Isolation and 
shRNA Construct for Tcf7l2 Knockdown 
Primary  hepatocytes  were  isolated  from 
wild-type and Tcf7l2+/- mice using the standard col-
lagenase method [40]. The cells were plated in Wil-
liams E medium supplemented with 100 U/ml peni-
cillin, 100 μg/ml streptomycin, 0.1% bovine albumin, 
0.1 μM dexamethasone, 2  mM l-glutamine, 1 X ITS 
(100 X Insulin-Transferrin-Selenium; Invitrogen) at a 
density  of  1.5  ×  105  cells/cm2  on  collagen-coated 
6-well  plates  (BD).  After  attachment  (2–3  hours), 
hepatocytes  were  maintained  in  the  completed  me-
dium with 0.25 mg/ml Matrigel (BD Biosciences) for 
16 hours followed by RNA extraction or regular me-
dium change and lentivirus transduction as described 
below.  
The oligonucleotides encoding a shRNA specific 
for  the  Tcf7l2  sequence  were  subcloned  into  the 
shRNA expression vector pGreen-puro containing the 
H1  promoter  (System  Bioscience,  Mountain  View, 
CA).  The  sense  oligonucleotide  is: Int. J. Biol. Sci. 2012, 8 
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5'-GATCCACTCACACCTCTCATCACGTTTCAAGA
GAACGTGATGAGAGGTGTGAGTTTTTTG-3',  and 
the  antisense:  5'-  AATTCAAAAAACTCACAC 
CTCTCATCACGTTCTCTTGAAACGTGATGAGAG
GTGTGAGTG-3'. For the scramble shRNA, the sense 
oligonucleotide  is:  5'-GATCCGAGAGTCAGT 
AAGGATAACATTTCAAGAGAATGTTATCCTTAC
TGACTCTCTTTTTG-3',  and  the  antisense: 
5'-AATTCAAAAAGAGAGTCAGTAAGGATAACAT
TCTCTTGAAATGTTATCCTTACTGACTCTC-3'. The 
successful  constructs  were  verified  by  sequencing. 
The  plasmids  were  packaged  into  lentivirus  with 
three other packaging plasmids VSV-G, REV and CPG 
(Cell  Biolabs  Inc.,  San  Diego,  CA)  in  HEK-293LTV 
cells.  Mouse  primary  hepatocytes  were  transducted 
by the lentivirus containing Tcf7l2 shRNA or scramble 
shRNA for 48 hours followed by RNA extraction.  
Islet Isolation and Measurement of Glucose- 
stimulated Insulin Secretion 
Islets at 11 weeks of age under a normal chow 
diet  or  after  9  weeks  on  the  HFD  were  aseptically 
isolated by collagenase digestion of mouse pancreas 
and  the  glucose-stimulated  insulin  secretion  was 
measured  in  batch  incubations  as  previously  de-
scribed [21].  
Histology 
Mouse liver at 11 weeks of age under a normal 
chow diet or after 9 weeks on the HFD was removed 
and pieces were fixed in 10 % (v/v) neutralized for-
malin solution (Sigma-Aldrich), embedded in paraf-
fin, sectioned at 5 µm, and stained with haematoxylin 
and eosin. For Oil Red O staining, frozen liver tissues 
embedded  in  O.C.T.  compound  (Tissue-Tek)  were 
used [22]. Stained liver sections were examined under 
a light microscope.  
Immunohistochemistry 
The pancreas from wild-type and Tcf7l2+/- mice 
at 11 weeks of age under a normal chow diet or after 9 
weeks on the HFD were fixed in 10 % (v/v) neutral-
ized formalin solution (Sigma-Aldrich), embedded in 
paraffin  and  sectioned  (5  µm).  For  immunohisto-
chemical analyses, sections were treated with 0.03% 
H2O2  in  methanol  for  15  min,  the  slides  were  then 
immersed in citrate buffer (0.01 M; pH 6.0) and incu-
bated for 25 min at 90 °C in a steam bath. Slides were 
washed  in  1x  Tris  Buffered  Saline  with  0.01% 
Tween-20 (TBST) and incubated in blocking solution 
(5% BSA in TBST) for 1 hour at room temperature to 
block  non-specific  binding.  The  primary  antibodies 
were goat anti-TCF-4 (1:200, Santa Cruz) and donkey 
rabbit anti−insulin antibody (1:200, Santa Cruz). Sec-
tions  were  incubated  in  an  antibody  solution  over-
night at 4 °C. The anti-TCF-4 antibody was visualized 
with Alexa Fluor® 568 donkey anti-goat IgG (H+L) 
(Invitrogen);  the  anti-insulin  antibody  was  detected 
with  Alexa  Fluor®  488  goat  anti-rabbit  IgG  (H+L). 
The  tissue  was  counterstained  lightly  with  DAPI. 
Digital images of stained sections were captured us-
ing a confocal microscope (Nikon).  
Measurement of Serum and Hepatic 
Triglyeride Content 
Blood from mice that had been food deprived for 
overnight at 11 weeks of age under a normal chow 
diet or after 9  weeks  on the HFD  was collected by 
cardiac puncture under deep anesthesia and placed 
on  ice.  Following  immediate  centrifugation  at  4°C, 
serum was separated and stored at -80 °C until analy-
sis for triglycerides. To extract lipids from the liver, 
each piece of tissues was weighed and homogenized 
in 4 ml of chloroform: methanol (2:1; v/v) mixture. 
One milliliter of PBS was then added, and the result-
ing suspension was mixed vigorously for 15 seconds 
then centrifuged at 1,500 g for 10 min at room tem-
perature.  Five-hundred  microliters  of  the  organic 
phase  was  transferred  into  a  tube  and  evaporated 
under nitrogen gas at room temperature. The residue 
was  resuspended  in  200  l  of  10  %  Triton  X100  in 
methanol. Serum and hepatic triglyceride levels were 
determined  by  an  assay  kit  obtained  from  Sig-
ma-Aldrich. 
Quantitative Real-Time Polymerase Chain Reaction. 
Total  RNA  was  extracted  from  the  liver,  primary 
hepatocytes,  and  isolated  pancreatic  islets  of  mice 
using TRIzol (Invitrogen, Carlsbad, CA) in accordance 
with the manufacturer’s instruction. Total RNA (2 g) 
was  reverse  transcribed  to  a  complementary  DNA 
with high capability reverse transcript kit (Roche Ap-
plied  Science,  Indianapolis,  IN).  Quantitative  re-
al-time  polymerase  chain  reaction  (qRT-PCR)  was 
conducted on an ABI PRISM 7000 sequence detection 
system (Applied Biosystems, Foster City, CA) using 
SYBR Green (Applied Biosystems, Foster City, CA). 
All primers used in the study were designed by the 
software  Primer3.0  and  as  follows:  Tcf7l2: 
5-CACAGCTCAAAGCATCAGGA-3  and 
5-CTGCATGTGAAGCTGTCGTT-3;  G6pc: 
5-CATCAATCTCCTCTGGGTGGC-3  and 
5-TGTTGCTGTAGTAGTCGGTGTCC-3;  Fasn: 
5-AAGGCTGGGCTCTATGGATT-3  and 
5-GGAGTGAGGCTGGGTTGATA-3;  Acc2: 
5-CCTGTTGCCCAAGAGAGAG-3  and 
5-ACAGCGGTCAGGTCAAAGTT-3;  Cpt1a: 
5-ATGACGGCTATGGTGTTTCC-3  and 
5-GGCTTGTCTCAAGTGCTTCC-3;  Acox1: Int. J. Biol. Sci. 2012, 8 
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5-TTGGAAACCACTGCCACATA-3  and 
5-GCCAGGACTATCGCATGATT-3;  Srebp1c: 
5-TGATGCTACGGGTACACACC-3  and 
5-TTGCGATGTCTCCAGAAGTG-3;  Srebp2: 
5-CCAAGGAGAGCCTGTACTGC-3  and 
5-ACTGCTGGAGAATGGTGAGG-3;  Acc1: 
5-TGGCAGACCACTATGTTCCA-3  and 
5-GTTCTGGGAGTTTCGGGTTC-3;  Scd1: 
5'-CTGACCTGAAAGCCGAGAAG-3'  and 
5'-GATGAAGCACATCAGCAGGA-3'.  All  gene  ex-
pression results were normalized to an internal con-
trol  with  the  following  primer  set:  Gapdh: 
5-TCAACGGATTTGGTCGTATTG-3  and 
5-GCTCCTGGAAGATGGTGATG-3. 
Statistical Analysis 
All  of  the  experiments  were  repeated  at  least 
twice. All data were expressed as the mean ± standard 
deviation  (SD).  Statistical  analyses  were  performed 
with the two-tailed Student’s t-test. A P value < 0.05 
was considered statistically significant. 
Results 
Generation of Tcf7l2 Knockout Mice 
To explore the potential in vivo role of TCF7L2 
gene, we generated the mice of which the Tcf7l2 gene 
was  disrupted  by  insertion  of  a  LoxP  site  together 
with  an  FRT  flanked  neomycin  selection  cassette 
within the intron 4 of mouse Tcf7l2 gene and a single 
distal  LoxP  in  the  intron  5  downstream  of  exon  5 
(Figure 1A), using the “knock-out first strategy” [23]. 
During the breeding, we could not obtain Tcf7l2 ho-
mozygous  null  mice  (Tcf7l2-/-),  consistent  with  pre-
vious reports that Tcf7l2-/- mice died within ~ 24 h of 
birth  [24,  25].  We  therefore  utilized  heterozygous 
Tcf7l2+/- mice for the remaining study. To determine 
the Tcf7l2 transcript levels, quantitative RT-PCR was 
performed in isolated islets and livers of mice at 11 
weeks of age. As shown in Figure 1B, there were sig-
nificantly  decreases  in  Tcf7l2  expression  up  to  55% 
and 45% in the isolated islets and livers, respectively, 
of  Tcf7l2+/- mice  compared  with  those  of  wild-type 
mice.  These  results  indicated  that,  as  expected,  the 
insertion of the cassette within Tcf7l2 locus had dis-
rupted the gene locus and led to decrease in  Tcf7l2 
mRNA expression in the heterozygotes.  
 
Figure 1. Generation of Tcf7l2 knockout mice. (A) Targeting construct for mouse Tcf7l2 knockout. There is insertion of a LoxP site and 
an FRT flanked neomycin selection cassette within intron 4 and a single distal LoxP in intron 5 downstream of exon 5. Detailed information 
is available from the IKMC web portal (http://www.knockoutmouse.org). (B) qRT-PCR analysis of mouse Tcf7l2 mRNA levels in islets and 
liver from wild-type (+/+, n = 3) and Tcf7l2 +/- (+/-, n = 3) mice at 11 weeks of age. (**) p < 0.01, (***) p < 0.001 compared with the 
wild-type mice. Int. J. Biol. Sci. 2012, 8 
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Metabolic Phenotypes of Tcf7l2 Heterozygous 
Mice 
We monitored the body weight of Tcf7l2+/- and 
wild-type mice beginning from the age of 2 weeks. On 
a normal chow diet, there was no significant differ-
ence in body weight between the two genotypes of 
mice  until  6  weeks  of  age.  From  6  weeks  of  age, 
Tcf7l2+/-  mice  exhibited  a  significantly  less  body 
weight  than  that  observed  in  the  wild-type  mice 
(Figure 2A). At 11 weeks of age, Tcf7l2+/- mice showed 
12 % less body weight compared with wild-type mice 
(P < 0.001). Whereas the liver mass/body weight ratio 
between Tcf7l2+/- and wild-type mice were not signif-
icantly  different,  the  visceral  fat  mass/body  weight 
ratio decreased in Tcf7l2+/- mice at 11 week old (Figure 
2B and 2C). In addition, we observed that the Tcf7l2+/- 
mice fed with the normal chow diet had reduced lev-
els of fasting glucose and insulin (Figure 2D and 2E), 
but the level in serum triglyceride was not statistically 
significant when compared to wild-type mice (Figure 
4C). Importantly, compared with the wild-type mice, 
Tcf7l2+/- mice showed an improved glucose tolerance 
(Figure 2F). In islets from Tcf7l2+/- mice at 12 weeks 
old,  basal-  and  glucose-stimulated  insulin  secretion 
did not differ between the wild-type and the Tcf7l2+/- 
mice fed on the normal chow diet (data not shown).  
 
Figure 2. Metabolic characterization of Tcf7l2 +/- mice and wild-type mice on a normal chow diet (NCD). (A) Growth curve for wild-type 
(■, n = 6) and Tcf7l2 +/- (▲, n = 7) mice from 2 to 11 weeks of age. The Tcf7l2 +/- mice had a significantly less body weight than the wild-type 
mice since week 6. (B, C) Percentages of liver and visceral fat weight normalized by body weight in wild-type (+/+, n = 6) and Tcf7l2 +/- (+/-, 
n = 7) mice. (D, E) Fasting blood glucose and serum insulin levels in wild-type (+/+, n = 6) and Tcf7l2 +/- (+/-, n = 7) mice. (F) Intraperitoneal 
glucose tolerance test (IPGTT) curves of wild-type (■, n = 6) and Tcf7l2 +/- (▲, n = 7) mice. Data are shown as mean ± standard deviation 
(SD). (*) p < 0.05, (**) p < 0.01, (***) p < 0.001 compared with the wild-type mice.  
 Int. J. Biol. Sci. 2012, 8 
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To  determine  whether  Tcf7l2+/-  mice  were  less 
prone to diabetes than wild-type mice, we fed mice on 
the  HFD  for  9  weeks.  As  shown  in  Figure  3A, 
HFD-fed  wild-type  mice  had  a  significantly  greater 
body  weight  than  Tcf7l2+/-  mice,  even  though  the 
body  weight  gain  in  both  groups  were  similar 
(wild-type : 73.9 ± 5.4 % vs. Tcf7l2+/- : 73.4 ± 8.0 % ) . 
The  food  intake  was  not  significantly  different  be-
tween  the  two  genotypes  (Figure  3B).  The  Tcf7l2+/- 
mice fed with the HFD had significantly less gains of 
liver and fat mass (Figure 3C and  3D). In addition, 
although the HFD caused an elevated levels of fasting 
blood  glucose  and  insulin  in  both  groups,  Tcf7l2+/- 
mice displayed significantly lower levels than those 
observed in wild-type mice (Figure 3E and 3F). Dur-
ing glucose tolerance tests in the HFD-fed mice, the 
change of blood glucose levels were also significantly 
different between wild-type and Tcf7l2+/- mice (Figure 
3G). The wild-type mice exhibited an impaired glu-
cose tolerance compared with the Tcf7l2+/-mice. The 
value of area under the glucose response curves in the 
Tcf7l2+/- mice was significantly lower than that in the 
wild-type mice (data not shown). The Tcf7l2+/- mice 
also showed a lower level of serum triglyceride (P < 
0.01, Figure 4C). 
 
Figure 3. Metabolic characteri-
zation  of  Tcf7l2  +/-  mice  and 
wild-type mice on a high fat diet 
(HFD).  (A)  Growth  curve  for 
wild-type (■, n = 7) and Tcf7l2 +/- 
(▲, n = 6) mice on a HFD from 
the ages of 13 weeks old for 9 
weeks. The Tcf7l2 +/- mice had a 
significantly less body weight than 
the  wild-type  mice  during  the 
period  of  HFD  treatment.  (B) 
Food intake in wild-type (■, n = 
7) and Tcf7l2 +/- (▲, n = 6) mice 
on a HFD. (C, D) Percentages of 
liver  and  visceral  fat  weight 
normalized  by  body  weight  in 
wild-type (+/+, n = 7) and Tcf7l2 
+/- (+/-, n = 6). (E, F) Fasting blood 
glucose and serum insulin levels 
in  wild-type  (+/+,  n  =  7)  and 
Tcf7l2 +/- (+/-, n = 6). (G) Intra-
peritoneal glucose tolerance test 
(IPGTT) curves of wild-type (■, n 
= 7) and Tcf7l2 +/- (▲, n = 6) mice 
on  a  HFD.  Data  are  shown  as 
mean ± SD. (*) p < 0.05, (**) p < 
0.01, (***) p < 0.001 compared 
with the wild-type mice.  
 Int. J. Biol. Sci. 2012, 8 
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Figure 4. In vivo effects of Tcf7l2 haploinsufficiency on liver histology, triglycerides and hepatic gene expression in mice. The age of mice 
and feeding duration are described in Materials and Methods. Representative hematoxylin-eosin (A) and Oil Red O (B) stained liver 
sections in wild-type (+/+) and Tcf7l2 +/- (+/-) mice fed on a NCD and a HFD. Scale bars 100 μm. Tcf7l2 +/- groups showed less hepatic fat 
deposits than wild-type groups. (C and D) Serum and hepatic triglyceride contents in wild-type (+/+, n = 4) and Tcf7l2 +/- (+/-, n = 4) mice. 
(E) qRT-PCR analysis of gluconeogenic and lipogenic gene expression in the liver from HFD-fed mice. Data are shown as mean ± SD. (*) 
p < 0.05, (**) p < 0.01 compared with the wild-type mice. (#) p < 0.05, (##) p < 0.01, (###) p < 0.001 compared with the NCD-fed mice.  
 
Regulation of Glucose and Lipid Homeostasis 
The liver contributes to regulate glucose and li-
pid  homeostasis  through  gluconeogenesis  and  lipo-
genesis [26, 27]. We found that the livers of Tcf7l2+/- 
mice were less pale and fatty as well as smaller than 
those of wild-type mice on the HFD. We histologically 
confirmed the decreased lipid deposition in the liver 
of  Tcf7l2+/-  mice  on  the  HFD.  In  contrast  to  the 
wild-type  mice  with  a  remarkable  hepatic  lipid  de-
posit, the Tcf7l2+/- mice had a normal liver histology 
and no steatosis after 9-week HFD (Figure 4A and 4B). 
The levels of triglyceride in the liver and serum were 
consistent with these histological findings (Figure 4C 
and 4D). We also determined gene expression associ-
ated  lipid  metabolism.  While  carnitine  palmito-
yltransferase 1a (CPT1a encoded by CPT1a) and pe-
roxisomal  acyl-coenzyme  A  oxidase  1  (ACOX1  en-Int. J. Biol. Sci. 2012, 8 
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coded by ACOX1) are thought to be the rate-limiting 
enzymes of the fatty acid β-oxidation, fatty acid syn-
thase  (FAS  encoded  by  FASN)  and  acetyl-CoA  car-
boxylase 2 (ACC-2 encoded by ACC2) are the genes 
associated  with  de novo  lipogenesis  [28].  In  Tcf7l2+/- 
mice fed with a normal chow diet, there was little or 
no effect on hepatic expression of Fasn, Acc2 and Cpt1a 
but  significantly  decreased  Acox1  expression  com-
pared with in wild-type mice. Interestingly, Tcf7l2+/- 
mice fed with a HFD showed increased expressions of 
Cpt1a  and  Acox1 as  well  as  reduced  expressions  of 
Fasn and Acc2 (Figure 4E), in line with the histological 
results. However,  we did  not detect any significant 
differences in the expression of sterol regulatory ele-
ment-binding  protein  gene  1c  (Srebp1c),  Srebp2, 
ACC-1,  and  stearoyl-Coenzyme  A  desaturase  1 
(Scd-1),  which  are  also  critical  lipogenic  genes,  be-
tween the wild-type mice and the Tcf7l2+/- mice. Since 
glucose homeostasis was improved in Tcf7l2+/- mice 
as shown by the IPGTT (Figure 2F and 3F), we also 
determined hepatic gene expression involved gluco-
neogenesis  (Figure  4E).  Glucose-6-phosphatase 
(G6Pase, which is encoded by G6PC) and phosphoe-
nolpyruvate  carboxykinase  (PEPCK1,  which  is  en-
coded by  PCK1) are thought to be  the rate-limiting 
enzymes involved in in hepatic gluconeogenesis [6]. 
On a normal chow diet, Tcf7l2 haploinsufficiency did 
not  significantly  affect  hepatic  expression  of  these 
glucose  homeostasis  genes.  However,  on  the  HFD, 
Tcf7l2+/- mice exhibited a significantly decreased G6pc 
expression,  while  it  showed  slightly  increased  Pck1 
expression (Figure 4E). The increased Pck1 expression 
seemed contradictory to the data of decreased blood 
glucose (Figure 3E) and improved glucose intolerance 
(Figure 3G). To ensure this was not a false result, we 
knocked  down  Tcf7l2  expression  in  the  primary 
hepatocytes isolated from wild-type mice and meas-
ured the expression of G6pc and Pck1. The shRNA via 
lentivirus achieved more than 70% of  Tcf7l2 knock-
down  efficiency  in  the  mouse  primary  hepatocytes 
(data  not  shown).  We  observed  that  the  Tcf7l2 
knockdown caused more than 70% decrease in G6pc 
expression (p < 0.001), while it resulted in approxi-
mately 1-fold increase in  Pck1 expression (p < 0.05) 
(data not shown).  
High-fat Diet Regulates Tcf7l2 Expression in a 
Tissue-specific Manner 
Several  literatures  have  reported  TCF7L2  ex-
pression in pancreatic islet from type 2 diabetic pa-
tients [16-18]. To determine the Tcf7l2 expression in 
the mice fed with either normal chow diet or HFD, 
immunohistochemistry was carried out. Triple stain-
ing for TCF7L2, insulin and DAPI revealed localiza-
tion of TCF7L2 in β-cells of pancreatic islet. As shown 
in Figure 5A, Tcf7l2 was almost undetectable in the 
sections  of  pancreatic  islet  from  wild-type  and 
Tcf7l2+/- mice fed with the normal chow diet. In con-
trast,  TCF7L2  expression  was  upregulated  in  the 
wild-type mice, but not much in the Tcf7l2+/- mice fed 
the HFD (Figure 5B). We also determined the Tcf7l2 
expression in the  liver from wild-type and Tcf7l2+/- 
mice.  Interestingly,  Tcf7l2  expression  was 
down-regulated in the liver when the mice were fed 
on the HFD (Figure 6). 
 
Figure 5. Expression of Tcf7l2 in mouse pancreatic sections from wild-type (+/+) and Tcf7l2 +/- (+/-) mice fed on a NCD (A) and a HFD 
(B). Scale bars 50 μm. The Immunohistochemistry was conducted as described in the Materials and Methods. Int. J. Biol. Sci. 2012, 8 
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Figure 6. Expression of mouse Tcf7l2 in the liver from wild-type (+/+, n = 3) and Tcf7l2 +/- (+/-, n = 3) mice fed on either NCD or HFD. 
The age of mice and feeding duration are described in the Materials and Methods. (**) p < 0.01 compared with the wild-type mice. (#) p < 
0.05, (##) p < 0.01 compared with the NCD-fed mice. 
 
Discussion 
In  the  present  study,  we  described  that  Tcf7l2 
haploinsufficiency had an effect on glucose- and lipid 
homeostasis in vivo, suggesting the role of TCF7L2 in 
metabolic regulation and type 2 diabetic susceptibil-
ity.  We  showed  that  global  reduction  of  Tcf7l2  ex-
pression led to not only a decrease in the level of cir-
culating glucose but also an improved glucose toler-
ance (Figure 2 and 3). These phenotypes are consistent 
with those in a recent report [25], where exon 11 of 
mouse  Tcf7l2  was  disrupted.  Although  a  detailed 
profile of gene expression alteration following Tcf7l2 
expression change has yet to be characterized to de-
fine the effect of Tcf7l2 on hepatic gluconeogenesis, 
our observation of metabolic phenotypes might be at 
least  partially  due  to  a  decreased  hepatic  glucose 
production in the Tcf7l2+/- mice. We detected a sig-
nificant  decrease  in  the  expression  of  G6pc,  a 
rate-limiting  enzyme  in  hepatic  gluconeogenesis  in 
the  liver  from  Tcf7l2+/-  mice  and  the  wild-type  pri-
mary hepatocytes of Tcf7l2 knocked-down. Indeed, it 
has been shown that disruption of WNT signaling by 
Cre  recombinase-mediated  deletion  of  β-catenin  re-
duces the mRNA abundance of G6PC and PCK1 both 
in  vitro  and  in  vivo  [6].  However,  we  surprisingly 
found  a  slightly  increase  in  the  expression of  Pck1, 
another  rate-limiting  enzyme  in  hepatic  gluconeo-
genesis  in  the  liver  from  Tcf7l2+/-  mice  and  the 
wild-type  primary  hepatocytes  of  Tcf7l2 
knocked-down, despite the decreased blood glucose 
and  improved  glucose  intolerance  in  the  Tcf7l2+/- 
mice. It is possible that the Pck1 expression increase is 
due to a feedback mechanism secondary to the more 
dramatic  G6pc  suppression  by  Tcf7l2  knockdown. 
Tcf7l2 is a transcription factor that may work as either 
an activator or repressor [41]. It would also be inter-
esting  to  examine  the  direct  roles  of  Tcf7l2  on  the 
transcription of G6pc and Pck1 respectively. Lastly, the 
decreased  blood  glucose  and  improved  glucose  in-
tolerance in the Tcf7l2+/- mice may be reflective of im-
proved  glucose  utilization  due  to  the  global  Tcf7l2 
knockdown in the whole body. Further in vivo studies, 
in particular the characterization of glucose disposi-
tion and global gene expression using tissue-specific 
Tcf7l2 knockout mice, are needed to confirm our re-
sults and explore the function of hepatic TCF7L2 in 
pathophysiology of type 2 diabetes.  
Obesity and type 2 diabetes are highly associated 
with hepatic steatosis, which is accompanied by not 
only  impaired  insulin  clearance,  but  also  impaired 
inhibition  of  hepatic  glucose  output  [29-31].  In  this 
study, we accelerated hepatic steatosis by feeding a 
HFD  in  wild-type  and  Tcf7l2+/- mice.  We  observed 
that  HFD-fed  wild-type  mice  exhibited  a  uniformly 
pale fatty liver and hepatomegaly. Intriguingly, these 
phenotypes  were  abolished  by  Tcf7l2  haploinsuffi-
ciency.  There  was  no  significant  difference  in  food 
intake between the wild-type and the Tcf7l2+/- mice. 
However, the Tcf7l2+/- mice under a HFD displayed a 
reduced expression of Fasn and Acc-2, which are as-
sociated with de novo lipogenesis, as well as increased 
expression of Cpt1a and Acox1, the genes for fatty acid 
oxidation [28]. The effect of Tcf7l2 expression on the 
transcription of  Cpt1a and Acox1 was also observed 
with primary hepatocytes isolated from the wild-type 
mice and the Tcf7l2+/- mice (data not shown). These 
changes in gene expression caused by Tcf7l2 down-
regulation may contribute to the improvement of di-
et-induced hepatic steatosis, even though the changes 
seemed to be mild and need to be confirmed by direct 
analysis such as indirect calorimetric analysis [32]. In 
addition,  visceral  adiposity  is  associated  with  in-
creased rates of lipolysis and fat deposition in those Int. J. Biol. Sci. 2012, 8 
 
http://www.biolsci.org 
800 
vital metabolic organs including the liver [27]. On the 
HFD,  wild-type  mice  displayed  a  higher  extent  of 
visceral adiposity, which seemed to fail to adequately 
store excess triglyceride and contribute to the elevated 
serum  triglyceride  levels.  It  should  be  noted  that 
Tcf7l2  is  ubiquitously  expressed  in  different  mouse 
tissues. It is thus likely that the metabolic phenotypes 
observed in the Tcf7l2+/- mice may also result from a 
global Tcf7l2 function change in multiple tissues, and 
the  molecular  mechanism  underlying  the  effect  of 
Tcf7l2 haploinsufficiency on nutrient metabolism re-
mains to be fully characterized.  
Both  increased  and  decreased  TCF7L2  expres-
sions in β-cells have been associated with altered in-
sulin secretion and  β-cell  apoptosis in human islets 
[16-20]. Recently, Gaulton et al. reported that the re-
gion surrounding the diabetic risk allele of the SNP 
(rs7903146) at  TCF7L2 is in a more open chromatin 
state than is the non-risk C allele in human pancreatic 
islets [33]. They also showed that the T allele had a 
greater enhancer activity than the C allele by using an 
in vitro reporter gene assay. Similar results were re-
ported by Stitzel et al [34]. These studies suggest an 
effect  associated  with  the  risk  allele  of  the  TCF7L2 
gene, whereby its open chromatin status leads to in-
creased transcription of the gene [33-34]. In our study, 
TCF7L2 expression was upregulated  by feeding the 
HFD in the pancreatic islets of wild-type mice, but not 
much  in  the  Tcf7l2+/-  mice  (Figure  5B).  In addition, 
although islet transcript level of Tcf7l2, as expected, 
was  only  about  50%  in  Tcf7l2+/-  mice  compared  to 
wild-type  mice,  there  were  no  apparent  defects  in 
insulin  secretion.  Tcf7l2+/-  mice  exhibited  normal 
pancreatic histology. We did not detect any difference 
in glucose-stimulated insulin secretion in the isolated 
islets  between  the  two  genotypes  either.  Our  data 
suggest that while a minimal Tcf7l2 expression is re-
quired for normal insulin secretion in vivo; enhanced 
expression may interfere with islet function, confer-
ring a metabolic risk. Overall, our in vivo results favor 
that a global overexpression of TCF7L2 may lead to an 
increased  susceptibility  to  type  2  diabetes.  In  con-
sistent  with this  hypothesis, Savic  et al. recently re-
ported that Tcf7l2 over-expressing transgenic mice are 
likely  to  develop  diabetes  and  glucose  intolerance 
after a HFD feeding, showing the reciprocal pheno-
types compared to the heterozygous Tcf7l2 null mice 
[25].  
Interestingly, the regulation of TCF7L2 expres-
sion  seems  to  be  varied  in  different  tissues.  In  our 
mouse study with the HFD, the expression levels of 
Tcf7l2  in  pancreatic  islets  was  upregulated  (Figure 
5B), whereas it was down-regulated in the liver (Fig-
ure 6). Consistently, Hindle et al. reported that hepatic 
expression of TCF7L2 is decreased in diabetic patients 
as  their  body  mass  index  (BMI)  increase  [35].  Cur-
rently, we do not know if a decreased Tcf7l2 expres-
sion  in  the  liver  is  simply  protective  as  a  feedback 
mechanism  during  metabolic  disregulation.  Fur-
thermore, TCF7L2 gene is known to display a complex 
pattern  of  spliced  variants  with  several  alternative 
exons and splice sites. These TCF7L2 splice variants 
are  distributed  in  a  tissue-specific  manner,  which 
could  strongly  influence  tissue-specific  effects  of 
TCF7L2 as a nuclear effector of WNT signaling [36-39]. 
Although studies have shed a light on the effect of 
TCF7L2 expression on metabolic homeostasis, further 
investigation is required to make informative conclu-
sions  of  the  functional  consequences  of  the  tis-
sue-specific regulation of TCF7L2 expression, e.g. via 
utilization of in vivo model targeting Tcf7l2 in a tis-
sue-specific  manner.  It  would  also  be  intriguing  to 
examine  the  functional  consequences  of  human 
TCF7L2 genetic polymorphisms in different tissues.  
In  summary,  the  current  study  demonstrated 
that TCF7L2 plays an important role in regulation of 
glucose and lipid metabolism, wherein its biological 
function change may cause alteration in the suscepti-
bility to type 2 diabetes. Our findings may provide 
insights into the etiology of type 2 diabetes and im-
portant information essential for evaluating the role of 
TCF7L2 in metabolic regulation.  
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